terbinafine (Lamisil)

From Aaushi
Jump to navigation Jump to search

Introduction

Tradename: Lamisil. (terbinafine hydrochloride)

Indications

Contraindications

Pregnancy category B.

Not recommended in pregnant women.

Not recommended in nursing mothers.

pregnancy category = b

safety in lactation = -

safety in lactation = ?

Dosage

Tabs: 250 mg.

Pharmacokinetics

elimination via liver

elimination via kidney

1/2life = 11-16 hours

1/2life = 8-16 days

Monitor

Adverse effects

(% vs placebo)

Overdose:

* see hepatotoxicity for management of toxicity

Drug interactions

Mechanism of action

More general terms

References

  1. The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996.
  2. Drug Information & Medication Formulary, Veterans Affairs, Central California Health Care System, 1st ed., Ravnan et al eds, 1998
  3. Jump up to: 3.0 3.1 Medical Knowledge Self Assessment Program (MKSAP) 11, 19, American College of Physicians, Philadelphia 1998, 2022
  4. Jump up to: 4.0 4.1 Prescriber's Letter 11(3):15 2004
  5. Jump up to: 5.0 5.1 Prescriber's Letter 11(4):21 2004
  6. deprecated reference
  7. Prescriber's Letter 17(7): 2010 Recommended Lab Monitoring for Common Medications Liver Function Test Scheduling Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=260704&pb=PRL (subscription needed) http://www.prescribersletter.com
  8. Jump up to: 8.0 8.1 Deprecated Reference

Database